atitis C virus (HCV), human immunodeficiency viruses (HIV-1 and HIV-2). and human T-cell lymphotropic virus (HTLV-I and HTLV-11). A direct detection of these viruses would be more effective for the prevention of transfusion-transmitted infections than the indirect measurement of the variable host immune response to these agents. Because the polymerase chain reaction (PCR) for viral gene amplification offers the most sensitive and direct means of detecting viruses in blood, we have developed a nonisotopic PCR procedure for the detection of HBV, chosen as a prototype. The problems, common to previously described PCR methods, of nucleic acid extraction and inhibition of the PCR by plasma proteins were overcome by isolation of HBV from plasma by means of 450-pm polystyrene beads covalently coated with monoclonal antibody to the Pre-S, region of the viral envelope protein. Detergent lysis and proteinase K digestion of the immunocaptured virions isolated from plasma released the HBV DNA. A modified PCR-am-
HE ACQUIRED immunodeficiency syndrome (AIDS)
T epidemic has changed the way physicians and patients perceive the safety of hemotherapy. Currently, blood-collection facilities perform a battery of immunoassays for detecting the markers of infection with blood-borne viruses, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency viruses (HIV-1 and HIV-2), human Tcell lymphotropic virus (HTLV-I and HTLV-II), and cytomegalovirus (CMV).' Since the currently used multiple immunoassays commonly detect either viral antibodies or, less commonly, detect the viral antigens themselves, it would be desirable to develop an assay system for the direct detection of viral genomes. With our growing knowledge about the nucleotide sequences of the blood-borne viruses and gene amplification by the polymerase chain reaction (PCR), the development of a sensitive assay for each of the BBVs is fea~ible.*.~ This approach may lower the incidence of false-negative test results because of an absence of the immunologic markers during early viremia, antigenic drift in persistent viral infections, or variations in the host immune response. Further, the direct detection of blood-borne viruses by PCR could reduce the waste of valuable blood units because of false-positive test results of the commonly used enzyme immunoassays (EIA). Toward this purpose, our research has been focused on HBV as a prototype of blood-borne viruses.
The detection of HBV DNA by nucleic acid hybridization analysis has been established as a sensitive and direct marker for viral replication and consequent infectivity. However, the detection limit of nucleic acid hybridization in dot-blot analysis of cloned HBV DNA has been demonstrated to be only 0.1 pg, corresponding to approximately 30,000 copies of the viral genome? For the detection of HBV in plasma, PCR is more sensitive than the dot-blot analysis and closely compares with infectivity testing in chimpanzees; however, plasma proteins inhibit amplification efficiency and consequently the plification protocol, incorporating digoxigenin-labeled dUTP in the amplified gene products followed by hybridization with a specific biotinylated oligonucleotide probe bound to streptavidin-coated 2.8-pm magnetic beads, allowed flow cytometric analyses of HBV-specific PCR products by means of antibodies to digoxigenin labeled with fluorescein isothiocyanate. The endpoint serial dilutions of pedigreed human plasma samples containing chimpanzee infectious dose (CIDSO) of 1 O7 for adw and CIDSo of 1 07.5 for the ayw subtypes were compared in repeated testing of PCR products by our immunoreactive bead (PCR-IRB) assay. HBV DNA was consistently detected in a 5 X 1 O-'O dilution of each sample. In testing 20 coded specimens of blood donors, with or without serologic markers of HBV infection, the PCR-IRB was specific and more sensitive than the PCR analyses by slot blot hybridization with radioactive probe. The PCR-IRB assay can be adapted for simultaneous detection of multiple blood-borne viruses by an automated flow cytometric analysis system. sensitivity of PCR.' To overcome this inhibition, nucleic acid purification with phenol/chloroform is required before the performance of PCR.'-'
We report here the development of a method involving the specific capture of HBV by antibody-coated polystyrene beads. This procedure facilitates the removal of PCR inhibitors, such as plasma proteins, before releasing HBV DNA from the immunocaptured virions and PCR amplification. Simultaneous PCR amplification and incorporation of digoxigenin-1 1 -dUTP,8 an analogue of thymidine-5'-triphosphate (TTP) in the PCR reaction, followed by hybridization with an oligonucleotide probe coupled to microbeads, and reaction with antibodies to digoxigenin labeled with fluorescein isothiocyanate, enabled flow cytometric analyses of the amplified gene products.
ceived from the Food and Drug Administration Center for Biologic Research and Evaluation.' The HBV/udw was derived from an asymptomatic chronic camer and had a chimpanzee infectious dose (CID,,) of 10-7/mL. The HBVlayw was a pool of serial bleedings from a single patient with acute hepatitis B and had a CIDm of mL. The hepatitis B surface antigen (HBsAg) by radioimmunoassay was detectable at dilutions 10 to 100 times lower than those proven infectious in chimpanzee^.'.'^ A third specimen was plasma from an asymptomatic chronic camer (W.M.) of HBsAg. To evaluate the performance of the noisotopic detection of amplified HBV DNA, 20 specimens of blood donors, with or without serologic markers of HBV infection, were selected and coded for PCR tests. Serial IO-fold dilutions of each specimen were made in fetal bovine serum (FBS) and stored as 200-pL aliquots at -70°C.
Blue-dyed polystyrene beads 400 to 450 pm in size (Polysciences, Inc, Wamngton, PA) were rehydrated with phosphate-buffered saline (PBS) for 2 hours, washed three times with PBS, and 2.5 mg of the beads were resuspended in 5 mL of 8% glutaraldehyde in PBS. The beads were mixed on an end-to-end rocking mixer for 4 hours at room temperature, washed three times with PBS, and then 50 pg of the monoclonal antibody to Pre-S I region of HBsAg (Abbott Laboratories, Chicago, IL) was added to 600 beads. After mixing overnight at room temperature, the beads were washed three times in PBS and then resuspended in 2.5 mL of 0.2 mol/L ethanolamine with gentle agitation for 30 minutes. To block nonspecific protein-binding sites, the beads were resuspended in 2.5 mL of PBS containing 0.5% bovine serum albumin (BSA; Polysciences Inc, Wamngton, PA) for 30 minutes at room temperature. Similarly, monoclonal antibodies (MoAbs) to the pre-S2 region of HBsAg and to the common "a" determinant of HBsAg (Abbott Laboratories, Chicago, IL) also were used in the immunoaffinity isolation of virions from the plasma (W.M.) for a functional evaluation of PCR amplification of HBV DNA.
The 5' biotinylated oligonucleotide probe, BGY3 (ACTGTTCAAGCCTCCAAGCTG-TGCCTTGGGTGGCTTTGGGGC), was obtained from Clonetech (Palo Alto, CA). Fifty picomoles of BGY3 were added to IO7 streptavidin-coated, superparamagnetic polystyrene beads (2.8 pm in diameter; Dynal, Inc, Great Neck, NY) in 100 pL of PBS and incubated at room temperature for 30 minutes with gentle agitation. The beads were washed three times with PBS, separated with a magnetic particle concentrator (Dynal), and resuspended in 100 pL of PBS.
Two hundred-microliter aliquots of IO-fold dilutions of the test plasma were mixed with 50 beads coated with antibodies and incubated overnight at 37°C with gentle agitation to capture HBV. After three washes with 300 pL of I X Taq buffer (50 mmol/L KCI, IO mmol/L tris-hydroxymethylaminomethane [TRIS], pH 8.3, 2.0 mmol/L MgCI2, 0.01% gelatin), the beads were resuspended in 100 pl of lysis buffer (50 mmol/L KC1, 10 mmol/L Tns pH, 8.3, 2.0 mmol/L MgClz, 0.5% Nonidet P-40, 0.5% polyoxyethylene sorbilan monolaurate [Tween 20; Sigma, St Louis, MO] containing 250 pg/mL of proteinase K, and incubated at 60°C for 1 hour. Proteinase K was then inactivated at 95°C for 20 minutes. Twenty-microliter aliquots of the supernatant were stored at -70°C. For each experiment, 200 pL of FBS and PCR grade water were used as negative controls. For conventional PCR, 200-pL aliquots of serial 10-fold dilutions of serum specimens were digested with lysis buffer (50 mmol/L KCI, IO mmol/L TRIS, pH 8.3, 2.5 mmol/L MgCI2, 0.5% Nonidet P-40,0.5% Tween 20, and 0.5% SDS) containing 200 &mL proteinase K and incubated overnight at 37"C, after which the proteinase K was denatured at 100°C for 10 minutes, followed by phenol/chloroform/isopropanol extraction and precip itation as previously described.' The pellet was resuspended in 50
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pL of Tris-EDTA (TE) buffer, pH 8.0, half of which was used for PCR.
PCR. Conventional PCR, followed by slot blot hybridization, and autoradiography were performed, as previously described by Ulrich et al. 5 Fig I) , 0.5 pmol/L of the primer GY2 (GAGTGCGAATCCACACTC, nucleotide no. 2377 to 2360), and IO pl of the sample. The primers were selected on the basis of sequence alignment of five HBV isolates and annealed to conserved regions of the HBV genome for amplifying a 630-bp fragment (Fig I) . The reaction was run through 40 cycles of amplification in a DNA Thermal Cycler (Perkin-Elmer Norwalk, CT). After the initial denaturation at 94°C for 1 minute, each cycle comprised denaturation at 94°C for 30 seconds, annealing at 40°C for 30 seconds, and extension at 72°C for 1 minute. Final extension was at 72°C for 5 minutes.
Relative performance of the following four different procedures was evaluated: (1 ) Ten-microliter aliquot of amplified HBV DNA was added to 10 pL of probe-coated beads (4 X IO5) in hybridization buffer (HB, 60 mmol/L NaCI, 40 mmol/L EDTA). After 2 minutes at 94°C for denaturation, the samples were hybridized for 30 minutes at 60°C. (2) Ten microliters of amplified DNA were denatured at 94°C for 2 minutes, chilled on ice, and then IO pL of probe-coated beads (4 X IO') in HB were added. Hybridization was carried out at 60°C for 30 minutes. (3) Ten microliters of amplified product were denatured at 94°C for 2 minutes, chilled on ice, 2 pmol/L ofthe oligonucleotide probe added, and hybridized at 60°C for 30 minutes. Then magnetic streptavidincoated beads (4 X IO') were added and incubated at room temperature for 30 minutes. (4) Ten microliters of amplified HBV DNA were added into IO pL of HB containing 2 pmol/L of the oligonucleotide probe, denatured at 94°C for 2 minutes, and hybridized at 60°C for 30 minutes. Then the magnetic streptavidin-coated beads (4 X IO') were added and incubated at room temperature for 30 minutes. After capture of amplified DNA to beads, the beads were washed three times with buffer (100 mmol/L TRIS, pH 8.0, 10 mmol/L EDTA, 50 mmol/L NaCI, 0.0 I % NP-40, and 0.0 1 % Tween 20) at room temperature with gentle agitation for 5 minutes. envelope protein). Each of the three MoAbs was evaluated for relative efficiency of the immunoaffinity procedure in yielding HBV DNA amplifiable in a conventional PCR procedure using hybridization with a 32P-labeled oligomer probe. The anti-HBs and antGPre42 yielded amplifiable HBV DNA from and dilutions of W.M. plasma, respectively. However, the anti-Pre-S 1 yielded amplifiable HBV DNA from IO-'' dilution of W.M. plasma. After three independent repeat experiments yielded similar results of amplifiable HBV DNA, the anti-Pre-S1 was selected as the immunoaffinity substrate for further experimental work on the development of PCR-IRB procedure. Because normal human serum and FBS gave comparable results in preliminary work and because FBS was used as a diluent for plasma samples, we used FBS as an HBV-negative control in standardization of PCR-IRB assay.
Immunofluorescent detection of ampliJied
Incorporation of digoxigenin-11-dUTP into amplified HBV DNA. In order to obtain optimal conditions for PCR amplification and dig-1 1-dUTP incorporation, we tested three different proportions of dTTP and dig-1 1 -dUTP on HBV DNA as a template. HBV was isolated from a 5 X IO-' dilution of the pedigreed adw plasma by immunocapture with anti-Pre S 1, whereas normal human serum, FBS, and water were used as three negative controls. After amplification, the PCR product was incubated with probe-coated beads, followed by reaction with 1 : 100 dilution of fluorescent antidigoxigenin, and then analyzed by flow cytometry. For each of the three dTTPdig-1 1-dUTP proportions (51, lO:l, 20: I), five independent experiments were performed and the results showed no significant difference. The assay is highly reproducible, as judged by the small standard deviation of the MCF values. The MCF for normal human serum and FBS were very similar, and hence FBS was consistently used as the negative control. The specimen to control ratio (S/C) of the MCF for each of the 5: 1, 10: 1, and 20: 1 proportions were calculated as 2.29, 2.52, and 2.34, respectively. Therefore, we selected 10: 1 proportion of dTTPdig-1 1-dUTP for further work on PCR-IRB.
Hybridization of digoxigenin-labeled, amplijied DNA to probe-coated beads. Four different experimental methods (described above) were tested to determine the optimal hybridization conditions for digoxigenin-labeled, amplified HBV DNA binding with the biotinylated probe. Methods (1) and (2), where the oligonucleotide was immobilized on the beads prior to hybridization, gave higher absolute MCF values and also higher S/C ratios than methods (3) and (4) ( Table  I ). In methods (3) and (4), hybridization of the oligonucleotide and amplified DNA was performed in solution prior to capturing the hybrids onto streptavidin beads. These results suggest that the binding between streptavidin-coated beads and the hybrids consisting of biotinylated probe and amplified DNA is impaired in these latter methods. Based on the results, method ( I ) was the optimal hybridization procedure because it gave the highest absolute MCF value, the highest S/C ratio, and was methodologically easier to perform. Optimization of fluorescent antidigoxigenin concentration. We tested six different dilutions of fluorescein-labeled antidigoxigenin for the detection of digoxigenin-labeled, amplified HBV DNA. The results of three independent experiments with each antibody concentration are shown in Table  2 . The S/C MCF ratio was optimal with 1:lOO dilution of the antidigoxigenin and the nonspecific MCF values for both HBV DNA and negative controls increased at higher concentrations of the fluorescein-labeled antidigoxigenin. The 1 : 100 dilution was optimal in regard to the specific and nonspecific binding of the antibody; ie, the optimal S/C ratio was 2.53.
Evaluation of nonradioactive detection of amplified DNA by flow cytometry. Three well-characterized HBV-positive human plasma samples (adw, ayw, and W.M.) were used for the evaluation of our PCR-IRB assay standardized as above. We analyzed, in duplicate, serial IO-fold dilutions of these samples. Six independent measurements of FBS were used as a negative control and gave a mean MCF of 278 k 30. Therefore, using a seven times standard deviation of the mean MCF for FBS, we calculated 488 as the cut-off value for PCR-IRB positivity. Table 3 shows the mean of four measured MCF values 4 SD for the serial IO-fold dilutions ranging from 5 X IO-' to 5 X IO-" for each of the adw, ayw, and W.M. plasma specimens. The data show that PCR-IRB detected HBV DNA in both adw and ayw plasma specimens at 5 X lo-'' and lower dilutions. The 5 X IO-'' and greater dilutions of W.M. plasma gave results close to the cut-off value of 488 but were considered negative; all lower dilutions ofthe W.M. plasma were positive for amplifiable HBV DNA.
Consecutive 20 plasma specimens of healthy blood donors, with or without serologic markers of HBV infection, when tested under code, showed that PCR-IRB consistently performed as well or better than the conventional PCR slot blot hybridization with radioisotope-labeled probe, as shown in Table 4 . After PCR amplification, both slot blot hybridization and the PCR-IRB detected HBV DNA in all HBsAg-positive specimens and also in an anti-HBc reactive specimen (no. 17) from an HBsAg-negative blood donor. Excepting specimen no. IO, PCR-IRB detected HBV DNA in each plasma at dilutions 10-to 1,000-fold higher than that for slot blot hybridization.
DISCUSSION
PCR has been reported to detect a single copy of a specific DNA sequence out of the total DNA sequences from lo5 cells.' However, purification of viral DNA from the infected plasma is necessary because of an inhibitory effect of plasma proteins on the performance of PCR.5-7 By coupling the highaffinity anti-Pre-S1 monoclonal antibody onto polystyrene beads for immunocapture of HBV particles from the test plasma, we have simplified the recovery of viral DNA and overcome the inhibitory effect of the human plasma proteins on PCR. The yield of HBV DNA amplifiable by PCR was relatively greater when anti-Pre-S I was used (in comparison with anti-Pre-S2 or anti-HBs) for immunoaffinity isolation of the virions. This is consistent with the fact that the Pre-SI region contains the viral receptor for hepatocytes?" thus enabling the anti-Pre-S 1 to preferentially capture the virions over the excess of DNA-free HBsAg circulating in the blood of infected persons. We have demonstrated this improved yield of HBV DNA amplifiable in both the conventional PCR with radioactive probe hybridization as well as our PCR-IRB. Data indicate mean MCF 2 SD of three independent experiments. The specimen/control (S/C) ratio was used as a guide for selection of optimal antibody dilution.
For personal use only. on October 25, 2017. by guest www.bloodjournal.org From Our data demonstrate that (1) consistent with previous reports,' ',I2 HBV DNA can be released from the bead-captured virions by detergent lysis and digestion with proteinase K for successful amplification by PCR; (2) digoxigenin-labeled dUTP can be used for nonradioactive labeling of amplified HBV DNA sequences during PCR; (3) digoxigenin, linked to dUTP via an 1 1-atom linear spacer, does not have any adverse effect on the hybridization of the PCR products with biotinylated probe prebound to streptavidin-coated magnetic beads; and (4) the hybridized products of PCR can be detected by flow cytometric analysis of the magnetic beads after reaction with FITC-labeled antidigoxigenin.
HBsAg is only detectable by immunoassays in the plasma at dilutions 10 to 100 times lower than the proven infectivity of dilutions of for adw and for ayw following inoculation in chimpanzee^.'.'^ The conventional PCR and hybridization with radiolabeled probes could detect HBV DNA in the same dilutions or a 10-fold greater dilution than the infectious dose in chimpanzees5 Similarly, the previously reported PCR procedures with immunocapture of HBV have detected HBV DNA in a 10-fold greater dilution than the infectious dose in chimpanzees.",'2 In this study, the PCR-IRB could consistently detect HBV DNA in a 1,000-fold greater dilution than the infectious dose in chimpanzees. If five copies of cloned HBV DNA are reliably amplifiable by the conventional PCR,5 our results could be interpreted to mean that chimpanzee infectious dose of HBV may be as high as 5,000 virions. However, it must be recognized that PCR is unable to discriminate between the infectious and the defective interfering particles or replication-incompetent virions; even sterilized or dead virions can also yield positive PCR results. We used freshly collected serum specimens for a direct comparison between PCR-IRB and slot blot hybridization of PCR-amplified HBV DNA. The results in Table  4 confirm that the detection limit of PCR-IRB in most cases of blood donors is IO-to 1,000-fold greater than the slot blot hybridization. This unprecedented sensitivity may be attributed to our unique PCR-IRB assay using isolation of virions with anti-Pre-S1 and getting rid of the inhibitors of PCR from human plasma more effectively than the phenol extraction and ethanol precipitation.
In conclusion, the higher sensitivity, specificity, and nonradioactive solid-phase probe that is comparable in cost with the conventional radioactive detection procedure, render PCR-IRB assay potentially useful for clinical diagnosis and therapeutic monitoring of viremia in HBV-infected patients. We have recently adapted the IRB test used for the detection of anti-HIV by Scillian et all3 to design a totally automated blood-screening system (manuscript in preparation). Similarly, the PCR-IRB lends itself to automation, with possible simultaneous amplification of the Viral nucleic acids for direct detection of various blood-borne viruses. For personal use only. on October 25, 2017. by guest www.bloodjournal.org From
